Inflammatory bowel disease events rare with IL-17s for hidradenitis suppurativa
Interleukin-17 therapy for hidradenitis suppurativa was not associated with an increased risk for inflammatory bowel disease, according to a study published in JAMA Dermatology. Of the 2,572 patients with HS who were treated with an IL-17 inhibitor across 10 randomized clinical trials, only six experienced new-onset IB
